Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

Fig. 4

S109 perturbs the core pathways associated with glioma by promoting the nuclear retention of tumor-suppressor proteins. a U87 cells were treated with vehicle or S109 (2 μM) for 12 h. The cytoplasmic and nuclear protein extracts were analyzed by immunoblotting with the indicated antibodies. b U87 and U251 cells were cultured in the absence or presence of S109 for 24 h. Cell lysates were then prepared and analyzed by immunoblotting. c S109 disrupts the interaction of CRM1 with tumor-suppressor proteins. U87 cells were treated with S109 (2 μM) for 2 h. Cell lysates were immunoprecipitated using CRM1 antibody and evaluated by western blotting. d–i The cells were treated with vehicle, LMB (2 nM) or S109 at the indicated concentrations for 12 h. The localization of Foxo1, p21, and p53 was analyzed by fluorescence microscopy

Back to article page